Physician profile
Stephen Miranda
NPI 1023544343
$10,415.52
in general payments reported to CMS, 2019-2025
11 companies · $8,604 in 2025
The $8,604 reported for 2025 was more than what 84% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $314 · 2024: $1,497 · 2025: $8,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,397 · Honoraria: $2,500 · Food and Beverage: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,396.79 |
| Honoraria | $2,500.00 |
| Food and Beverage | $2,204.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tulavi Therapeutics, INC. | $7,081.49 | 2025 | Allay Nerve Cap - Small Nerve Set |
| Medical Device Business Services, INC. | $810.36 | 2025 | Velys |
| Stryker Corporation | $775.69 | 2022-2024 | Everest Spinal System, N/A |
| Depuy Synthes Sales INC. | $522.11 | 2024-2025 | Teligen, Symphony |
| Alphatec Spine, INC | $359.06 | 2024 | Identiti, Other - Miscellaneous |
| Integra Lifesciences Corporation | $166.98 | 2024-2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Axogen | $150.96 | 2025 | |
| Acclarent, INC | $148.24 | 2024 | Trudi Nav Cable |
| Surgalign Spine Technologies, INC. | $142.14 | 2022 | |
| Nalu Medical, INC. | $133.49 | 2025 | Nalu Neurostimulation System |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.